Pelthos Therapeutics Inc. PTHS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $27.7M+64.9% | $16.8M+127% | $7.41M— | $0— | $0— | ||
| $5.66M+42.0% | $3.99M+72.2% | $2.32M— | $0— | $0— | ||
| $22.04M+72.1% | $12.81M+152% | $5.09M— | $0— | $0— | ||
| 79.6%+3.3pp | 76.3%+7.5pp | 68.7%— | —— | —— | ||
| $1.22M-0.7% | $1.23M+7.8% | $1.14M-19.2% | $1.41M+55.3% | $906.96K-23.1% | ||
| $61.92M+45.8% | $42.45M+66.3% | $25.52M+239% | $7.53M— | —— | ||
| —— | —— | —— | —— | $7.51M-0.8% | ||
| -$43.68M-34.7% | -$32.43M-45.7% | -$22.25M-149% | -$8.94M-19.6% | -$7.47M+1.3% | ||
| -157.7%+35.4pp | -193.1%+107pp | -300.4%— | —— | —— | ||
| $5.23M+73.7% | $3.01M+66.8% | $1.81M+262% | $499K— | —— | ||
| —— | $5K-95.2% | $104.25K-48.8% | $203.5K-32.8% | $302.75K-24.7% | ||
| -$15.29M+16.3% | -$18.28M-918% | -$1.8M-1,686% | -$100.52K-191% | $110.47K+129% | ||
| -$58.98M-16.3% | -$50.71M-111% | -$24.05M-166% | -$9.04M-22.8% | -$7.36M+7.5% | ||
| -$7.39M0.0% | -$7.39M-1,489% | -$465K— | $0— | $0— | ||
| -$51.59M-19.1% | -$43.32M-83.7% | -$23.58M-161% | -$9.04M-22.8% | -$7.36M+7.5% | ||
| -186.2%+71.7pp | -257.9%+60.5pp | -318.4%— | —— | —— | ||
| —— | —— | —— | —— | -$13.91+2.5% | ||
| —— | —— | —— | —— | -$16.97-18.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | 12.7M-24.3% | ||
| $2.59M+66.3% | $1.56M+129% | $679K— | $0— | $0— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | -$7.93M+0.3% | ||
| —— | $285K+33.3% | $213.75K+50.0% | $142.5K+100% | $71.25K— | ||
| —— | $5K-95.2% | $104.25K-48.8% | $203.5K-32.8% | $302.75K-24.7% | ||
| $27.7M+64.9% | $16.8M+5,613% | $294K— | $0— | $0— | ||
| -$43.68M-34.7% | -$32.43M-45.7% | -$22.25M-149% | -$8.94M-19.6% | -$7.47M+1.3% | ||
| -$40.29M-31.9% | -$30.53M-41.5% | -$21.57M-141% | -$8.94M-19.6% | -$7.47M+1.3% | ||
| -$40.29M-31.9% | -$30.53M-41.5% | -$21.57M-141% | -$8.94M-19.6% | -$7.47M+1.3% | ||
| -145.4%+36.4pp | -181.8%+109pp | -291.3%— | —— | —— | ||
| -$43.68M-34.7% | -$32.43M-45.7% | -$22.25M-149% | -$8.94M-19.6% | -$7.47M+1.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Pelthos Therapeutics Inc.'s revenue?
- Pelthos Therapeutics Inc. (PTHS) generated $27.7M in revenue over the trailing twelve months.
- Is Pelthos Therapeutics Inc. profitable?
- Pelthos Therapeutics Inc. is not currently profitable: it reported a net loss of $51.6M over the trailing twelve months, a -186.2% net margin.
- What are Pelthos Therapeutics Inc.'s profit margins?
- Gross margin is 79.6% and operating margin is -157.7%, with a -186.2% net margin.
- What is Pelthos Therapeutics Inc.'s earnings per share?
- Pelthos Therapeutics Inc.'s diluted EPS over the trailing twelve months is $-13.44.
- Where does Pelthos Therapeutics Inc.'s income statement data come from?
- Every line is extracted from Pelthos Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
